Alemtuzumab and laquinimod results released Sanofi and its subsidiary Genzyme announced the results of a two-year study of 581 people with relapsing-remitting MS testing their experimental intravenous therapy alemtuzumab. Meanwhile, Teva Pharmaceutical Industries Ltd. and Active Biotech announced the results of a study involving more than 1,300 people with relapsing-remitting MS testing their oral drug laquinimod Read More...
For patients with severe psoriasis, a new class of intravenous and injectable biological medicines known as “biologics” has brought about a near revolution in treatment. But doctors at the University of Michigan Health System say patients and their doctors also should consider long-established treatment alternatives that are less expensive and avoid some of the risk factors associated with the immune system-suppressing biologics, such as increased risk of serious infection and lymphoma Read More...
South San Francisco, Calif. -- June 22, 2010 -- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) for the treatment of macular edema following retinal vein occlusion (RVO) Read More...
US Food and Drug Administration grants priority review status after accepting US regulatory submission for 0.5 mg once-daily Gilenia (fingolimod) US and European Union regulatory submissions completed in December 2009 for Gilenia include more than 4,000 patient years of clinical trial data Basel, February 22, 2010 - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicine Read More...
